Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity
Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data In "Nature" Demonstrating Potential Of ITK Inhibition With Soquelitinib As A Novel Approach To Modulate Tumor Immunity
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data highlighting the potential of soquelitinib, the Company's lead ITK inhibitor program, as a novel approach to modulate tumor immunity. The data was published in npj Drug Discovery (part of the Nature portfolio of journals), an open access, international, peer-reviewed journal dedicated to publishing the highest quality research relevant to all aspects of drug design and discovery.
Corvus Pharmaceuticals, Inc.（納斯達克股票代碼：CRVS）是一家臨床階段的生物製藥公司，今天宣佈了出版的前臨床數據，突出了公司領先的ITk抑制劑方案soquelitinib在調節腫瘤免疫中的潛力。這些數據發表在npj Drug Discovery（Nature期刊組合的一部分），這是一本開放獲取、國際性、同行評議的期刊，致力於發表與藥物設計和發現各個方面相關的最高質量研究。
The publication, entitled "Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity," includes a detailed overview of soquelitinib's mechanism of action – suppressing Th2 and Th17 cytokine production and sparing Th1 cytokines – that serves as a novel approach to cancer immunotherapy, both as a single agent and in combination with immune checkpoint inhibitors. The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function.
這篇名爲"合成和表徵soquelitinib的選擇性ITk抑制劑，調節腫瘤免疫"的論文包括了soquelitinib的作用機制概述——抑制Th2和Th17細胞因子的產生，保留Th1細胞因子——作爲癌症免疫療法的一種新方法，無論作爲單一藥物還是與免疫檢查點抑制劑聯合使用。數據還顯示，soquelitinib增加了細胞毒性CD8陽性T細胞的效應子功能，並導致記憶T細胞的增加，這些T細胞具有增強的效應子功能。
譯文內容由第三人軟體翻譯。
